Planet 13 Holdings (PLNH) Net Income towards Common Stockholders (2021 - 2026)

Planet 13 Holdings' (PLNH) quarterly Net Income towards Common Stockholders came in at -$8.1 million in Q1 2026, down 295.46% year-on-year from $4.1 million in Q1 2025, and down 215.53% on a QoQ basis from $7.0 million in Q4 2025.

Planet 13 Holdings (PLNH) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends

Planet 13 Holdings (PLNH) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$8.1 million in Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders fell 295.46% year-over-year to -$8.1 million in Q1 2026; TTM through Mar 2026 was -$58.3 million, a 32.69% decrease from a year earlier, with the FY2025 full-year figure at -$52.3 million, down 9.42% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at -$8.1 million, down from $7.0 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for PLNH reached as high as $7.0 million in Q4 2025 and fell as low as -$46.3 million in Q3 2023.
  • Historically, Net Income towards Common Stockholders has averaged -$14.2 million across 5 years, with a median of -$8.1 million in 2024.
  • Across the five-year window, Net Income towards Common Stockholders tumbled 2131.73% in 2022 and surged 126.5% in 2025, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at -$42.1 million in 2022, then jumped by 66.13% to -$14.3 million in 2023, then slumped by 85.43% to -$26.4 million in 2024, then jumped by 126.5% to $7.0 million in 2025, then plunged by 215.53% to -$8.1 million in 2026.
  • Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$8.1 million in Q1 2026, $7.0 million in Q4 2025, and -$44.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn 370.00 Mn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn -2.35 Bn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn 274.90 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn - -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn 57.00 Mn
10 Planet 13 Holdings 39.42 Mn 23.16 Mn 9.41 Mn -8.10 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -8.10 Mn
Dec 31, 2025 7.01 Mn
Sep 30, 2025 -43.96 Mn
Jun 30, 2025 -13.30 Mn
Mar 31, 2025 -2.05 Mn
Dec 31, 2024 -26.44 Mn
Sep 30, 2024 -7.41 Mn
Jun 30, 2024 -8.07 Mn
Mar 31, 2024 -5.87 Mn
Dec 31, 2023 -14.26 Mn
Sep 30, 2023 -46.25 Mn
Jun 30, 2023 -4.62 Mn
Mar 31, 2023 -8.48 Mn
Dec 31, 2022 -42.09 Mn
Sep 30, 2022 -6.32 Mn
Jun 30, 2022 -7.07 Mn
Mar 31, 2022 -4.06 Mn
Dec 31, 2021 -12.46 Mn
Sep 30, 2021 4.05 Mn
Jun 30, 2021 347,962.00